Ocular Therapeutix (NSDQ:OCUL) said today that the FDA approved its resubmitted application Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery.
The regulatory win for the Bedford, Mass.-based company comes after much back-and-forth with the FDA; the agency has twice rejected Ocular Therapeutix’s application for Dextenza.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix wins FDA nod for drug-delivery eye insert appeared first on MassDevice.